Phase II Trial of SOM230 (Pasireotide LAR) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 06 Sep 2016 Status changed from active, no longer recruiting to completed.
- 15 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 04 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.